Pipeline
|
Drug Substance |
Dosage Form |
Strenght |
Drug Delivery System |
Status of the Art (Stage / Phase) |
Mechanism of Action |
Indication |
Note |
|
Red Rise Monacoline Mevacolin(3%) Berberine |
Tablet |
333 mg (10 mg Monacoline) 225 mg |
Modified Oral Release |
Technical dossier to be prepared |
HMG CoA Reductase Inhibitor Antidiabetics |
Cholesterol lowering |
Available |
|
Red Rise Monacoline Mevacolin(3%) Berberine |
Tablet |
333 mg (10 mg Monacoline) 225 mg |
Improved Oral Release |
Feasibility |
HMG CoA Reductase Inhibitor Antidiabetics |
Cholesterol lowering |
Available |
|
Red Rise Monacoline Mevacolin(1.5%) |
Tablet |
200 mg (3 mg Monacoline) Q10 30mg Niacine 27mg |
Improved Oral Release |
Technical Dossier available (3 years stability ) |
HMG CoA Reductase Inhibitor |
Cholesterol lowering |
Available |
|
Red Rise Monacoline Mevacolin(3%) |
Tablet |
333 mg (10 mg Monacoline) |
Improved Oral Release |
Technical Dossier available (2 years stability ongoing) |
HMG CoA Reductase Inhibitor |
Cholesterol lowering |
Available |
|
Red Rise Monacoline Mevacolin(1.5%) |
Tablet |
200 mg (3 mg Monacoline) |
Modified Oral Release |
Technical Dossier available (2 years stability ongoing) |
HMG CoA Reductase Inhibitor |
Cholesterol lowering |
Available |
|
Red Rise Monacoline Mevacolin(3%) |
Tablet |
333 mg (10 mg Monacoline) |
Modified Oral Release |
Technical Dossier available (1 years stability ongoing) |
HMG CoA Reductase Inhibitor |
Cholesterol lowering |
Available |
|
Curcumine 95% |
Tablet |
500 mg 250 mg |
Gastrointestinal Target Release |
Technical Dossier to be prepared |
Anti inflammatory |
Ulcerative Colitis |
Available |
|
Omega 3 Fatty acid Fish Oil Monacoline Mevacolin(3%) |
Capsule |
610 mg DHA 110mg EPA 165mg 100mg(3mg) |
Liquid Improved Modified Oral Release |
Technical Dossier to be prepared (1 year stability ongoing) |
Lipid lowering HMG CoA Reductase Inhibitor |
Cholesterol lowering HLD > LDL < |
Available |
|
Menthol |
Tablet |
50 mg |
Gastrointestinal Target Release |
Technical Dossier ready (2 years stability ongoing) |
Colonic activation of TRPM8 Inhibition of TRPA1 |
Irritable Bowel Syndrome |
Available with Clinical Trial (30 patients) |